PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Targeted therapy with apatinib in a patient with relapsed small cell lung cancer: A case report and literature review.

Abstract Small cell lung cancer (SCLC) is a lethal malignancy. Once relapsed, the disease is irreversible and most of the patients will die of cancer aggravation in 1 to 2 months. In the past several decades, little progress has been made in the systemic treatment of SCLC. Apatinib, as a novel small-molecule tyrosine kinase inhibitor specifically targeting the vascular endothelial growth factor receptor 2 (VEGFR2), has achieved progress in treatment of a variety of cancers. However, there has been no report of the targeted therapy with apatinib in SCLC yet.
PMID
Related Publications

Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.

Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.

The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature.

Significant efficacy and well safety of apatinib combined with radiotherapy in NSCLC: Case report.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29390367
OWN - NLM
STAT- MEDLINE
DCOM- 20180212
LR  - 20180212
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 50
DP  - 2017 Dec
TI  - Targeted therapy with apatinib in a patient with relapsed small cell lung cancer:
      A case report and literature review.
PG  - e9259
LID - 10.1097/MD.0000000000009259 [doi]
AB  - RATIONALE: Small cell lung cancer (SCLC) is a lethal malignancy. Once relapsed,
      the disease is irreversible and most of the patients will die of cancer
      aggravation in 1 to 2 months. In the past several decades, little progress has
      been made in the systemic treatment of SCLC. Apatinib, as a novel small-molecule 
      tyrosine kinase inhibitor specifically targeting the vascular endothelial growth 
      factor receptor 2 (VEGFR2), has achieved progress in treatment of a variety of
      cancers. However, there has been no report of the targeted therapy with apatinib 
      in SCLC yet. PATIENT CONCERNS: A 63-year-old man, an ex-smoker, presented with a 
      slight hoarseness and cough. The patient was admitted to our department with a
      primary diagnosis of SCLC at an extensive stage (ES-SCLC). After 17 months of
      successful first-, second-, and third-line chemotherapy, the disease eventually
      became relapsed. Then, apatinib treatment started promptly on demand by the
      patient and his family. INTERVENTION: After presenting an informed consent, the
      patient received apatinib treatment immediately at a dose of 250 mg/day orally.
      OUTCOMES: (1) On the 28th day of apatinib therapy, the symptoms of dyspnea and
      poor appetite of the patient were notably improved. (2) The CT scan taken on the 
      70th day showed that the pleural effusion in the left lung almost disappeared.
      (3) The elevated serum neuron-specific enolase (NSE) level was decreased. The
      patient died of acute respiratory failure on the 172nd day of apatinib treatment.
      Importantly, the tumor mass did not enlarge obviously during apatinib treatment. 
      LESSONS: Here, we presented a case with relapsed SCLC who unexpectedly responded 
      to single-agent apatinib treatment. Therefore, this report will shed light on
      future studies of targeted therapy with apatinib in SCLC at different stages.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Zhao, Jun
AU  - Zhao J
AD  - Department of Oncology, Changzhi People's Hospital, Changzhi, Shanxi.
FAU - Zhang, Xiaoling
AU  - Zhang X
AD  - Department of Oncology, Changzhi People's Hospital, Changzhi, Shanxi.
FAU - Gong, Chaojie
AU  - Gong C
AD  - Department of Geriatrics, Shanghai First People's Hospital, Shanghai Jiao Tong
      University, Shanghai.
FAU - Zhang, Jialei
AU  - Zhang J
AD  - Department of Anesthesiology, Changzhi People's Hospital, Changzhi, Shanxi,
      China.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
SB  - AIM
SB  - IM
MH  - Fatal Outcome
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Pyridines/*therapeutic use
MH  - Small Cell Lung Carcinoma/*drug therapy
EDAT- 2018/02/03 06:00
MHDA- 2018/02/13 06:00
CRDT- 2018/02/03 06:00
PHST- 2018/02/03 06:00 [entrez]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/02/13 06:00 [medline]
AID - 10.1097/MD.0000000000009259 [doi]
AID - 00005792-201712150-00117 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(50):e9259. doi: 10.1097/MD.0000000000009259.